Nivolumab monotherapy plus salvage nivolumab/ipilimumab demonstrated superior treatment-free survival rates among patients with advanced renal cell carcinoma, especially in patients with favorable risk profiles.
Monotherapy with nivolumab (Opdivo) and salvage nivolumab/ipilimumab (Yervoy) in nonresponder patients with advanced renal cell carcinoma (aRCC) demonstrated notable treatment-free survival (TFS) and toxicity-free TFS, according to a subgroup analysis of the phase 2 HCRN GU16-260 study (NCT03117309).1
At 36 months, 68.3% of the 128 patients with clear cell aRCC were alive following first-line nivolumab monotherapy and salvage nivolumab plus ipilimumab. These were patients who experienced disease progression. This included 96.8% of patients with favorable risk profiles and 56.6% with intermediate- or poor-risk profiles. The mean TFS at 36 months for the overall population was 9.4 months, and 65.6% of favorable-risk and 27.1% of intermediate-/poor-risk patients were alive and had not received subsequent systemic treatments.
According to authors of the study published in the Journal for ImmunoTherapy of Cancer, “TFS can be used as a novel clinical trial end point that complements commonly used efficacy measures such as median [progression-free survival (PFS)], median overall survival [OS], objective response rate, and duration of response. TFS is particularly evident with immunotherapy, as the majority of tumor responses are durable and can be maintained after treatment stops.”
The 36-month mean OS was 29.9 months (95% CI, 27.9-31.8) for the overall population. In patients with favorable-risk profiles, the mean OS was 35.7 months (95% CI, 35.3-36.2) compared with 27.4 months (95% CI, 24.9-29.9) in the intermediate- to poor-risk profile group.
Similar TFS advantages were observed in CheckMate 214 (NCT02231749). In the phase 3 CheckMate 214 trial, which investigated nivolumab plus ipilimumab vs sunitinib (Sutent) in patients with aRCC, 86% of patients who experienced a complete response sustained that response. At 30 months, 55% of these responders were alive and did not receive subsequent systemic treatment.2 Comparatively, similar TFS was not observed with sunitinib, which is a VEGFR tyrosine kinase inhibitor-based therapy, where the mean TFS was 4.4 months at the 60-month follow-up point.
These findings support the idea that this immunotherapy could be a “functional cure,” according to study authors, which surveyed patient data identifies as the most favorable outcome for aRCC.1
“This ability to stop treatment and remain free of subsequent treatment initiation for extended periods of time is of particular benefit to favorable-risk patients, many of whom are asymptomatic from their disease at the time of treatment initiation and, thus, could have their quality of life negatively impacted by the side effects of prolonged treatment,” study authors concluded.
Key Takeaways From QOL and Use of Steroids With IO-Based RCC Regimens
May 6th 2024During a Case-Based Roundtable® event, Ulka Vaishampayan, MBBS, discussed the safety and quality-of-life data for ipilimumab plus nivolumab in patients with advanced renal cell carcinoma in the second article of a 2-part series.
Read More
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
Comparing Choices for IO/TKI Combinations in Advanced RCC
May 2nd 2024During a Case-Based Roundtable® event, Shilpa Gupta, MD, led a discussion on the combination of immunotherapy and tyrosine kinase inhibitors for patients with advanced renal cell carcinoma in the second article of a 2-part series.
Read More
Beyond the First-Line: Economides on Advancing Therapies in RCC
February 1st 2024In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.
Listen
Roundtable Roundup April: Renal Cell Carcinoma
April 27th 2024In separate, live virtual events, Arnab Basu, MD, MPH, and Robert J. Motzer, MD, asked participants which therapy they would choose for a patient with clear cell renal cell carcinoma (RCC) and why they would make that choice.
Read More
Advances in Subsequent Therapies Shake Up Sequencing of ccRCC Treatment
April 25th 2024With the approval of belzutifan and other newer data for treating patients with recurrent renal cell carcinoma, the state of subsequent therapies is advancing beyond the reuse of frontline options with impacts on duration of response and quality of life.
Read More